E-ISSN 2231-3206 | ISSN 2320-4672
 

Original Research

Online Publishing Date:
30 / 10 / 2021

 


Early detection of kidney diseases in diabetic patients with serum cystatin-C

T Padmaja.


Abstract
Background: Prevalence of chronic kidney disease (CKD) is increased worldwide. According to Kidney Disease Improving Global Outcomes guidelines, CKD is defined as abnormalities of kidney structure or function, present for >3 months with implications for health. In individuals with Type-2 diabetes, assessment of kidney function is mandatory, as diabetic nephropathy constitutes the major cause of CKD which leads to end-stage renal disease in diabetic patients. Cystatin-“C”, an alternative biomarker of kidney function, is a better predictor of CKD and is less affected by age, race, or muscle mass. Hence, the presence of elevated serum cystatin C is directly linked with risk of developing a progressive form of CKD.

Aim and Objectives: This study aims to evaluate the importance of serum cystatin C as a marker for early detection of CKD in diabetic and non-diabetic patients.

Materials and Methods: A total of 25 non-diabetics with CKD (Group-I) and 25 diabetics with CKD (Group-II) were included in the study. Cystatin C and glucose were estimated in the serum sample. Latex-enhanced immunoturbidimetric assay method was used for the estimation of serum cystatin-C. Random blood glucose was estimated using glucose oxidase-peroxidase method. Student’s t-test was used for comparison between CKD with non-diabetics and CKD with diabetics by SPSS statistical package version 20.0. “P” < 0.05 was considered as statistically significant. The results of the two groups are expressed as Mean ± SD.

Results: Serum cystatin-C levels were significantly increased (P < 0.001) in Group-I when compared to Group-II. There was a significant negative correlation (r = –0.447, P < 0.001) between serum cystatin C and estimating glomerular filtration rate was observed, which indicates that there is a possibility of renal damage in non-diabetic subjects.

Conclusion: Cystatin C can be used as a good alternative marker compared to creatinine for assessing severe kidney damage.

Key words: Chronic Kidney Disease; Cystatin-C; Diabetes


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by T Padmaja
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

T Padmaja. Early detection of kidney diseases in diabetic patients with serum cystatin-C. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 571-575. doi:10.5455/njppp.2022.12.066184202123102021


Web Style

T Padmaja. Early detection of kidney diseases in diabetic patients with serum cystatin-C. https://www.njppp.com/?mno=86823 [Access: March 14, 2024]. doi:10.5455/njppp.2022.12.066184202123102021


AMA (American Medical Association) Style

T Padmaja. Early detection of kidney diseases in diabetic patients with serum cystatin-C. Natl J Physiol Pharm Pharmacol. 2022; 12(5): 571-575. doi:10.5455/njppp.2022.12.066184202123102021



Vancouver/ICMJE Style

T Padmaja. Early detection of kidney diseases in diabetic patients with serum cystatin-C. Natl J Physiol Pharm Pharmacol. (2022), [cited March 14, 2024]; 12(5): 571-575. doi:10.5455/njppp.2022.12.066184202123102021



Harvard Style

T Padmaja (2022) Early detection of kidney diseases in diabetic patients with serum cystatin-C. Natl J Physiol Pharm Pharmacol, 12 (5), 571-575. doi:10.5455/njppp.2022.12.066184202123102021



Turabian Style

T Padmaja. 2022. Early detection of kidney diseases in diabetic patients with serum cystatin-C. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 571-575. doi:10.5455/njppp.2022.12.066184202123102021



Chicago Style

T Padmaja. "Early detection of kidney diseases in diabetic patients with serum cystatin-C." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 571-575. doi:10.5455/njppp.2022.12.066184202123102021



MLA (The Modern Language Association) Style

T Padmaja. "Early detection of kidney diseases in diabetic patients with serum cystatin-C." National Journal of Physiology, Pharmacy and Pharmacology 12.5 (2022), 571-575. Print. doi:10.5455/njppp.2022.12.066184202123102021



APA (American Psychological Association) Style

T Padmaja (2022) Early detection of kidney diseases in diabetic patients with serum cystatin-C. National Journal of Physiology, Pharmacy and Pharmacology, 12 (5), 571-575. doi:10.5455/njppp.2022.12.066184202123102021